Den Europæiske Union - dansk - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystisk fibrose - andet respirationssystem produkter - orkambi tabletter er indiceret til behandling af cystisk fibrose (cf) hos patienter i alderen 6 år og ældre, der er homozygot for f508del-mutation i cftr-genet. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.